

16th Annual Indy Hematology Review

Saturday, March 9, 2019

JW Marriott Indianapolis
10 S. West Street
Indianapolis, IN

Presented by:



in collaboration with

MDAnderson
~~Cancer~~ Network[®]

A program of MD Anderson Cancer Center

Organized by:

Indy Hematology Education, Inc.



This Symposium is approved for 8.5 AMA PRA Category 1 Credit(s)[™],
8.0 CNE contact hours, and 8.0 CPE contact hours
by the Purdue University College of Pharmacy.

A full day of presentations by today's leaders in Hematology and Hematologic Malignancies

Gain comprehensive clinical content that will immediately impact your practice. This full-day symposium features a series of didactic lectures presented by the nation's top hematology experts from the Dana-Farber Cancer Institute, MD Anderson Cancer Center, Johns Hopkins School of Medicine, Lombardi Comprehensive Cancer Center, Mayo Clinic, and more!


The Indy Hematology Review brings together over 300 hematologists, oncologists, radiologists, physician assistants, oncology RN's, nurse practitioners, pharmacists, medical students, and other allied health professionals. Stay current with a concise summary of the critical data presented at the American Society of Hematology (ASH) annual meeting. Examine significant scientific updates in clinical hematologic research, learn how these updates directly affect the study and practice of hematology, and discover how new research can be translated into new patient care strategies.

Dive deeper into new advances and targeted treatments for:


- Multiple Myeloma
- Waldenström's Macroglobulinemia
- Benign and Non-Benign Hematology
- Indolent Lymphomas and Hodgkin's Lymphoma
- Acute Lymphoblastic Leukemia
- Chronic and Acute Myeloid Leukemias
- Myeloproliferative Neoplasms
- Myelodysplastic Syndrome
- Hematopoietic Stem Cell Transplantation

Visit the Exhibit Hall

Visit the exhibit hall to experience a showcase of the latest technology and research in hematology. The exhibit hall offers an opportunity to learn about a wide range of products and services offered by pharmaceutical companies, medical suppliers, biotechnology companies, healthcare systems, and research-based companies. Stop in for a beverage and snack at the "Physicians' Lounge" as you visit exhibitors.



SUPPORTERS & SPONSORSHIPS



The 2019 Indy Hematology Review is supported by:

AstraZeneca
Bristol-Myers Squibb
Immunomedics
Incyte
Pharmacyclics

PLANNING COMMITTEE

Ruemu Birhiray, MD (Chair)
CEO, Indy Hematology Education, Inc.
Partner and Vice President,
Hematology Oncology of Indiana, PC

Michael C. Wiemann, MD, FACP (Co-Chair)
President, Providence Hospital
Executive Vice President West Region,
St. John Providence Health System

Donna Birhiray, OTR, MBA
Indy Hematology Education, Inc.
Treasurer

Thalia Hammond
Indy Hematology Education, Inc.

Jennifer Wheeler-Terry, JD
Wabash College

Debbie Locklear
Meeting Services Unlimited, Inc.
President

Tina Machina, CMP
Meeting Services Unlimited, Inc.
Director of Conventions

INDY HEMATOLOGY EDUCATION, INC.

Indy Hematology Education, Inc. is a 501(c), non-profit corporation, incorporated on February 15, 2010, in the State of Indiana, with the following purposes:

- (a) Raise awareness and provide education regarding hematology and oncology diseases and disorders
- (b) To encourage youth to pursue careers in hematology and oncology and
- (c) To connect individuals suffering from or affected by hematology and oncology diseases and disorders to organizations, programs, and service providers.

BOARD OF DIRECTORS

Ruemu E. Birhiray, MD, President and CEO

Michael C. Wiemann, MD, FACP, Vice-President

Jennifer Terry, JD, Secretary and Director

Donna M. Birhiray, OT, MBA, Treasurer and Director

Thalia Hammond, Director

Register online: www.indyhematologyreview.com

MAIN SYMPOSIUM AGENDA

7:00 AM - 2:30 PM – Registration

7:00 AM - 5:00 PM – Exhibit displays

7:30 AM – Breakfast: Product Theaters

8:30 AM – State of the Art: 2019 Emerging Therapies in Hematologic Malignancies

Ruemu E. Birhiray, MD – Chair

CEO, Indy Hematology Education, Inc.

Associate Professor of Clinical Medicine,
Marian University of Osteopathic Medicine
Partner and Vice President, Hematology
Oncology of Indiana, PC (Indianapolis, IN)

9:00 AM – Multiple Myeloma:

Changing and Emerging Treatment Paradigms
Kenneth Anderson, MD

Kraft Family Professor of Medicine, Harvard
Medical School

Program Director of the Lebow Institute for
Myeloma Therapeutics and

Jerome Lipper Multiple Myeloma Center, Dana-
Farber Cancer Institute (Boston, MA)

**9:30 AM – Waldenström's Macroglobulinemia:
Beyond the Diagnosis**

Steven Treon, MD, MA, PhD

Associate Professor of Medicine, Harvard
Medical School

Senior Attending Physician for Medical
Oncology at DFCI and Brigham & Women's
Hospital

Director of the Bing Center for Waldenström's
Macroglobulinemia

Dana-Farber Cancer Institute (Boston, MA)

**10:00 AM – Chronic Lymphocytic Leukemia: How
to Treat in 2019**

Michael Keating, MB, BS

Clinical Professor of Medicine, Department of
Leukemia

Division of Cancer Medicine

The University of Texas MD Anderson Cancer
Center (Houston, TX)

10:30 AM – Break with Q & A

**10:45 AM – Indolent Lymphomas and
Hodgkin's Lymphoma: Achieving Curability**

Bruce Cheson, MD, FACP, FAAS, FASCO

Deputy Chief of Division of Hematology and
Oncology

Head of Hematology and Professor of Medicine
Lombardi Comprehensive Cancer Center
MedStar Georgetown University Hospital
(Washington, DC)

**11:15 AM – Aggressive B and T Cell
Lymphomas: Chemotherapy, Antibodies,
Immunotherapy**

John Leonard, MD

Attending Physician, New York-Presbyterian
Hospital

Richard T. Silver Distinguished Professor of
Hematology and Medical Oncology
Associate Dean of Clinical Research and Interim
Chair of Department of Medicine
Weill Cornell Medical College (New York, NY)

**11:45 AM – Not so Benign Hematology:
Complementopathies and Aplastic Anemia**
Robert Brodsky, MD

Director of Division of Hematology

Johns Hopkins Family Professor of Medicine
and Oncology

Johns Hopkins University School of Medicine
(Baltimore, MD)

**12:15 PM – Benign Hematology: Cytopenias,
Clotting, and Bleeding**

Craig Kessler, MD

Professor of Medicine and Pathology

Director of Clinical Coagulation Laboratory in
Division of Laboratory Medicine

Lombardi Comprehensive Cancer Center
MedStar Georgetown University Hospital
(Washington, DC)

12:45 PM – Q & A

1:00 PM – Lunch: Product Theaters

**2:00 PM – T. HOWARD LEE KEYNOTE
LECTURE:**

**Emerging Targeted Therapies for Follicular
Lymphomas: A Future Without Chemotherapy**
Pier Zinzani, MD, PhD

Professor of Hematology,
Head of Lymphoma Group
Institute of Hematology "L. e A. Seràgnoli"
University of Bologna (Bologna, Italy)

3:00 PM – Challenging Cases Presentation

Michael C. Wiemann, MD – Co-Chair

President of Providence Hospital

Executive Vice President West Region, St. John
Providence Health System (Warren, MI)

**3:05 PM – Chronic Myeloid Leukemia:
Targeted Therapy in 2019**

Richard Larson, MD

Professor of Medicine in Section of
Hematology/Oncology,
Director of Hematologic Malignancies Clinical
Research Program
The University of Chicago Comprehensive
Cancer Center (Chicago, IL)

**3:35 PM – Myeloproliferative Neoplasms:
Genetic Prognostication and Current
Treatment**

Ayalew Tefferi, MD, PhD

Professor of Hematology and Internal Medicine
Mayo Clinic (Rochester, MN)

**4:05 PM – Practical Considerations in
the Treatment of Polycythemia Vera and
Myelofibrosis**

Angela Fleischman, MD, PhD

Assistant Professor, Department of Medicine
Division of Hematology/Oncology
University of California, Irvine Health (Irvine, CA)

4:35 PM – Break with Q & A

**4:45 PM – Acute Lymphoblastic Leukemia:
Emerging and Targeted Therapies**

Hagop Kantarjian, MD

Samsung Distinguished University Chair in
Cancer Medicine,
Associate Vice President for Global
Academic Programs,
Professor and Department Chair,
Department of Leukemia, Division of
Cancer Medicine
The University of Texas MD Anderson
Cancer Center (Houston, TX)

**5:15 PM – Acute Myeloid Leukemias:
Treatment Options in 2019**

Martin Tallman, MD

Chief of Leukemia Service and Professor of
Medicine
Memorial Sloan-Kettering Cancer Center
Weill Cornell Medical College (New York, NY)

**5:45 PM – Myelodysplastic Syndrome;
How Much Further Do We Have To Travel?**

Richard Stone, MD

Attending Physician,
Brigham and Women's Hospital
Professor of Medicine,
Harvard Medical School
Director, Adult Leukemia Program
Dana-Farber Cancer Institute (Boston, MA)

**6:15 PM – Hematopoietic Stem Cell
Transplantation: How I Treat and When I
Transplant in 2019**

Richard Childs, MD, RADM, USPHS

Senior Investigator for Laboratory of
Transplantation Immunotherapy
Clinical Director, National Heart, Lung, and
Blood Institute (NHLBI)
National Institutes of Health (Bethesda, MD)

6:45 PM – Wrap Up and Adjourn

**7:00 PM – 8:30 PM – Challenging Cases
in Lymphoproliferative and Plasma Cell
Disorders / Interactive Meeting with the
Professors / Reception**

Paul Richardson, MD

R.J. Corman Professor of Medicine, Harvard
Medical School
Clinical Program Leader and Director of
Clinical Research of the Jerome Lipper
Multiple Myeloma Center, Dana-Farber
Cancer Institute (Boston, MA)

Sonali Smith, MD

Elwood V. Jensen Professor of Medicine
Director, Lymphoma Program
The University of Chicago (Chicago, IL)

NURSING SYMPOSIUM AGENDA

**8:30 AM – State of the Art: 2019 Emerging
Therapies in Hematologic Malignancies**

Ruemu E. Birhiray, MD – Chair

**9:00 AM – Indolent Lymphomas and
Hodgkin's Lymphoma**

Bruce Cheson, MD, FACP, FAAS, FASCO

**9:20 AM – Benign Hematology and
Coagulopathy**

Craig Kessler, MD

9:40 AM – Acute Leukemia and MDS

Richard Stone, MD

10:00 AM – Break with Q & A

10:15 AM – Aggressive Lymphomas

Sonali Smith, MD

10:35 AM – Chronic Leukemias

Michael Keating, MB, BS

10:55 AM – Break with Q & A

11:10 AM – Myeloproliferative Neoplasms

Ayalew Tefferi, MD, PhD

**11:30 AM – Recognition and Management
of Toxicities of Oral Therapeutics in
Hematologic Malignancies**

Michelle Wright Mast, FNP-BC

Nurse Practitioner, Hematology/Oncology
St. Vincent Medical Group (Indianapolis, IN)

**11:50 AM – Management of Long-Term
Survivors of Hematologic Malignancies**

Kristi Orbaugh, RN, MSN RNP, AOCN

Adult Nurse Practitioner
Community Hospital Oncology Physicians
(Indianapolis, IN)

**12:10 PM – Emesis and Nutritional
Strategies for Hematologic Malignancies**

12:30 PM – Multiple Myeloma

Paul Richardson, MD

12:50 PM – Break with Q & A

1:00 PM – Lunch: Product Theaters

**2:00 PM – Adjourn and join General Session
for T. Howard Lee Lecture**

Disclosure information, biographies, and slides (where authorized by the presenter)
will be available at indyhematologyreview.com

REGISTRATION

To register online, go to indyhematologyreview.com and click on "Register."

Early Bird Registration: ends February 1, 2019

Early Bird Physicians	\$185.00
Early Bird Physicians + CME Fee	\$210.00
Early Bird Allied Health & Nurses	\$110.00
Early Bird Allied Health & Nurses + CNE Fee	\$135.00
Early Bird Nurse Practitioners & Pharmacists	\$135.00
Early Bird Nurse Practitioners & Pharmacists + CPE Fee	\$160.00
Industry & Exhibitors	\$360.00

Standard Registration: after February 1, 2019

Physicians	\$235.00
Physicians + CME Fee	\$260.00
Allied Health & Nurses	\$160.00
Allied Health & Nurses + CNE Fee	\$185.00
Nurse Practitioners & Pharmacists	\$185.00
Nurse Practitioners & Pharmacists + CPE Fee	\$210.00
Industry & Exhibitors	\$360.00
Student/Fellow Scholarship* (Limited Number)	\$25.00
Nurse Scholarship* (Limited Number)	\$25.00

**A limited number of scholarships are available on a first-come, first-served basis.*

If you are registering clinicians for your office, fill in the attendee's full name and e-mail address so the post-event survey and continuing education credits are e-mailed to the attendee.

REFUND POLICY

Request a registration cancellation refund on or before February 22, 2019, to receive a Full Refund. After February 22, there is NO REFUND.

HOTEL RESERVATIONS

Make your reservation online at indyhematologyreview.com and click on "Hotel/Parking." You may also call the JW Marriott Indianapolis directly at 317-860-5800 or toll free at 1-888-236-2427. Mention "Indy Hematology Review" for the discounted group rate of \$192 plus tax (currently 17%). Access to the block of discounted rooms will close on Friday, February 15, 2019. Make your reservation early!

PARKING

Parking is available at the JW Marriott Indianapolis. 24-hour parking rates are currently: \$44.00 on-site parking; \$49.00 valet. **Rates are subject to change without notice.*

Self-parking is also available at the Government Center Washington St. Parking Facility, 401 West Washington Street. First Hour: \$15.00; Daily Maximum: \$25.00

QUESTIONS?

Please contact Erica Olivero, 317-713-1530, erica@conventionmanagers.com.

Register online: www.indyhematologyreview.com

CONTINUING EDUCATION INFORMATION

PHYSICIANS

LEARNING OBJECTIVES

At the completion of this activity, participants should be able to:

1. Discuss new emerging hematology therapies in general and for chronic Myeloid Leukemia, acute Promyelocytic and Myeloid Leukemia, and Myeloproliferative neoplasms.
2. Evaluate molecular diagnosis, targeted therapies, and resistance mechanisms of Waldenström's Macroglobulinemia to assist in disease recognition.
3. Discuss the advancement of immune check point inhibitors within hematologic malignancies and updated treatment paradigms presented at the American Society of Hematology meeting in San Diego, CA in December 2018.
4. Recommend new regimens for Hematopoietic Stem Cell transplantation and identification of transplant candidates.
5. Review the advancement in benign hematology research.
6. Review new treatment regimens in follicular lymphoma.

CME ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Indy Hematology Education, Inc. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

DESIGNATION STATEMENT

Purdue University College of Pharmacy designates this live activity for a maximum of **8.5 AMA PRA Category 1 Credit(s)[™]**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE STATEMENT

All faculty, staff, and reviewers involved in the planning, review, or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, staff, and reviewers of Indy Hematology Education, Inc. and Purdue University College of Pharmacy have no relationships to disclose.

NOTE: While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.

NURSES

CNE ACCREDITATION STATEMENT

Purdue University Continuing Nursing Education is accredited as a provider of continuing nursing education with distinction by the American Nurses Credentialing Center's Commission on Accreditation.

This program is approved for **8.0 contact hours**.

PHARMACISTS

CPE ACCREDITATION STATEMENT

Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution.

Universal Activity Number (UAN): 0018-9999-19-001-L01-P

This program is approved for **8.0 contact hours** (0.8 CEU's).

PHARMACY LEARNING OBJECTIVES

At the completion of this activity, participants should be able to:

1. Discuss new emerging hematology therapies in general and for chronic Myeloid Leukemia, acute Promyelocytic and Myeloid Leukemia, and Myeloproliferative neoplasms.
2. Evaluate molecular diagnosis, targeted therapies, and resistance mechanisms of Waldenström's Macroglobulinemia to assist in disease recognition.
3. Discuss the advancement of immune check point inhibitors within hematologic malignancies and updated treatment paradigms presented at the American Society of Hematology meeting in San Diego, CA in December 2018.
4. Recommend new regimens for Hematopoietic Stem Cell transplantation and identification of transplant candidates.
5. Review the advancement in benign hematology research.
6. Review new treatment regimens in follicular lymphoma.



Register online: www.indyhematologyreview.com